Ltd Nirland Sells 939,009 Shares of Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Stock

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) major shareholder Ltd Nirland sold 939,009 shares of Conduit Pharmaceuticals stock in a transaction on Monday, October 7th. The shares were sold at an average price of $0.10, for a total value of $93,900.90. Following the transaction, the insider now owns 6,092,000 shares in the company, valued at $609,200. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Ltd Nirland also recently made the following trade(s):

• On Friday, October 4th, Ltd Nirland sold 1,368,991 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.10, for a total value of $136,899.10.
• On Wednesday, October 2nd, Ltd Nirland sold 333,177 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.10, for a total value of $33,317.70.
• On Monday, September 30th, Ltd Nirland sold 1,016,823 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.12, for a total value of $122,018.76.

Conduit Pharmaceuticals Stock Performance

Conduit Pharmaceuticals stock opened at $0.11 on Wednesday. The business has a fifty day moving average of $0.15 and a two-hundred day moving average of $1.51. Conduit Pharmaceuticals Inc. has a twelve month low of $0.10 and a twelve month high of $7.83.

Conduit Pharmaceuticals (NASDAQ:CDT) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.07) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised Conduit Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.